HIV-infected ugandan women on antiretroviral therapy maintain HIV-1 RNA suppression across periconception, pregnancy, and postpartum periods

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 4, 2016, Pages 399-406

  Matthews, Lynn T ^a   Ribaudo, Heather B ^b   Kaida, Angela ^c   Bennett, Kara ^d   Musinguzi, Nicholas ^e   Siedner, Mark J ^a   Kabakyenga, Jerome ^e   Hunt, Peter W ^f   Martin, Jeffrey N ^f,g   Boum, Yap ^h   Haberer, Jessica E ^a   Bangsberg, David R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c SIMON FRASER UNIVERSITY   (Canada)

^d Bennett Statistical Consulting Inc   (United States)

^e MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^f Department of Medicine ^*  (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h EPICENTRE   (France)

Author keywords

Antiretroviral adherence; HIV 1; Periconception; Postpartum; Pregnancy; Uganda

Indexed keywords

EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CONCEPTION; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PATIENT MONITORING; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERIUM; SENSITIVITY ANALYSIS; UGANDAN; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DEVICES; DRUG ADMINISTRATION; DRUG MONITORING; GENETICS; HIV INFECTIONS; METABOLISM; MIDDLE AGED; ODDS RATIO; PREGNANCY COMPLICATIONS, INFECTIOUS; UGANDA; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; RNA, VIRAL; UGANDA; YOUNG ADULT;

EID: 84960321613     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000874     Document Type: Article

References (33)

1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
2. World Health Organization. Programmatic Update: Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Geneva, Switzerland: WHO; 2012.
3. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva, Switzerland: WHO; 2013.
4. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL. pdf. Accessed November 18, 2015.
5. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS. 2012;26:2039-2052.
6. Cavallo IK, Kakehasi FM, Andrade BA, et al. Predictors of postpartum viral load rebound in a cohort of HIV-infected Brazilian women. Int J Gynaecol Obstet. 2010;108:111-114.
7. Phillips T, Thebus E, Bekker LG, et al. Disengagement of HIV-positive pregnant and postpartum women from antiretroviral therapy services: a cohort study. J Int AIDS Soc. 2014;17:19242.
8. Henegar CE, Westreich DJ, Maskew M, et al. Effect of pregnancy and the postpartum period on adherence to antiretroviral therapy among HIV-infected women established on treatment. J Acquir Immune Defic Syndr. 2015;68:477-480.
9. Tenthani L, Haas AD, Tweya H, et al. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ("Option B+") in Malawi. AIDS. 2014;28:589-598.
10. Kim MH, Ahmed S, Hosseinipour MC, et al. Implementation and operational research: the impact of option B+ on the Antenatal PMTCT cascade in Lilongwe, Malawi. J Acquir Immune Defic Syndr. 2015;68:e77-e83.
11. Uganda HIVAIDS Sero-behavioural Survey 2004-2005. Calverton, MD: Ministry of Health (Uganda) and ORC Macro; 2006.
12. Geng EH, Bwana MB, Kabakyenga J, et al. Diminishing availability of publicly funded slots for antiretroviral initiation among HIV-infected ART-eligible patients in Uganda. PLoS One. 2010;5:e14098.
13. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564-573.
14. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda AIDS. 2007;21:965-971.
15. Genberg BL, Wilson IB, Bangsberg DR, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26:1415-1423.
16. Filmer D, Pritchett LH. Estimating wealth effects without expenditure data-or tears: an application to educational enrollments in states of India. Demography. 2001;38:115-132.
17. Kaida A, Kastner J, Ng C, et al. Barriers and promoters to uptake of safer conception strategies among HIV-affected couples with fertility intentions in Mbarara, Uganda. Abstract 23.03. Paper Presented at: HIVR4P; October 2014; Cape Town, South Africa.
18. Matthews LT, Bajunirwe F, Kastner J, et al. Barriers and Facilitators to Provider-initiated Assessment of Fertility Intentions Among Men and Women Living with HIV in Uganda. Abstract #TUPE125. Melbourne, Australia: International AIDS Society/AIDS 2014; 2014.
19. Matthews LT, Milford C, Kaida A, et al. Lost opportunities to reduce periconception HIV transmission: safer conception counseling by South African providers addresses perinatal but not sexual HIV transmission. J Acquir Immune Defic Syndr. 2014;67(suppl 4):S210-S217.
20. Siedner MJ, Musinguzi N, Tsai AC, et al. Treatment as long-term prevention: sustained reduction in HIV sexual transmission risk with use of antiretroviral therapy in rural Uganda. AIDS. 2014;28:267-271.
21. Sha BE, Tierney C, Cohn SE, et al. Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150. HIV Clin Trials. 2011;12:9-23.
22. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr. 2009;52:406-416.
23. Ngarina M, Popenoe R, Kilewo C, et al. Reasons for poor adherence to antiretroviral therapy postnatally in HIV-1 infected women treated for their own health: experiences from the Mitra Plus study in Tanzania. BMC Public Health. 2013;13:450.
24. Ngarina M, Kilewo C, Karlsson K, et al. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania. BMC Infect Dis. 2015;15:175.
25. Ciaranello AL, Perez F, Engelsmann B, et al. Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Clin Infect Dis. 2013;56: 430-446.
26. Price AJ, Kayange M, Zaba B, et al. Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study. Sex Transm Infect. 2014;90:309-314.
27. Kellerman SE, Ahmed S, Feeley-Summerl T, et al. Beyond prevention of mother-to-child transmission: keeping HIV-exposed and HIV-positive children healthy and alive. AIDS. 2013;27(suppl 2):S225-S233.
28. Matthews LT, Ashaba S, Psaros C, et al. From Option A to B+: Exploring challenges of navigating evolving PMTCT strategies among postpartum women living with HIV in rural Uganda. Abstract MO-PEB188. Paper presented at: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015); July 2015; Vancouver, Canada.
29. Campbell J, Burns BF, Natukinda S, et al. Social Support through observational trial Participation among HIV patients in Southwest Uganda. Paper presented at: 10th International Conference on HIV Treatment and Prevention Adherence June 29 2015; Miami, Florida.
30. Deschamps AE, Van Wijngaerden E, Denhaerynck K, et al. Use of electronic monitoring induces a 40-day intervention effect in HIV patients. J Acquir Immune Defic Syndr. 2006;43:247-248.
31. Sutton S, Kinmonth AL, Hardeman W, et al. Does electronic monitoring influence adherence to medication? Randomized controlled trial of measurement reactivity. Ann Behav Med. 2014;48:293-299.
32. Buchberg MK, Fletcher FE, Vidrine DJ, et al. A mixed-methods approach to understanding barriers to postpartum retention in care among low-income, HIV-infected women. AIDS Patient Care STDS. 2015;29:126-132.
33. Clouse K, Schwartz S, Van Rie A, et al. "What they wanted was to give birth; nothing else": barriers to retention in option B+ HIV care among postpartum women in South Africa. J Acquir Immune Defic Syndr. 2014; 67:e12-e18.